Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 567 of the 570 references it cites were found in a registry or an index.

Antifungal Drugs TDM: Trends and Update

Kably, Benjamin, Launay, Manon, Derobertmasure, Audrey, Lefeuvre, Sandrine, Dannaoui, Eric, Billaud, Eliane M. · 2022 · Therapeutic Drug Monitoring

Abstract

Purpose: The increasing burden of invasive fungal infections results in growing challenges to antifungal (AF) therapeutic drug monitoring (TDM). This review aims to provide an overview of recent advances in AF TDM. Methods: We conducted a PubMed search for articles during 2016–2020 using “TDM” or “pharmacokinetics” or “drug-drug-interaction” with “antifungal,” consolidated for each AF. Selection was limited to English language articles with human data on drug exposure. Results: More than 1000 articles matched the search terms. We selected 566 publications. The latest findings tend to confirm previous observations in real-life clinical settings. The pharmacokinetic variability related to special populations is not specific but must be considered. AF benefit-to-risk ratio, drug–drug interaction (DDI) profiles, and minimal inhibitory concentrations for pathogens must be known to manage at-risk situations and patients. Itraconazole has replaced ketoconazole in healthy volunteers DDI studies. Physiologically based pharmacokinetic modeling is widely used to assess metabolic azole DDI. AF prophylactic use was studied more for Aspergillus spp. and Mucorales in oncohematology and solid organ transplantation than for Candida (already studied). Emergence of central nervous system infection and severe infections in immunocompetent individuals both merit special attention. TDM is more challenging for azoles than amphotericin B and echinocandins. Fewer TDM requirements exist for fluconazole and isavuconazole (ISZ); however, ISZ is frequently used in clinical situations in which TDM is recommended. Voriconazole remains the most challenging of the AF, with toxicity limiting high-dose treatments. Moreover, alternative treatments (posaconazole tablets, ISZ) are now available. Conclusions: TDM seems to be crucial for curative and/or long-term maintenance treatment in highly variable patients. TDM poses fewer cost issues than the drugs themselves or subsequent treatment issues. The integration of clinical pharmacology into multidisciplinary management is now increasingly seen as a part of patient care.

Overview

Integrity signals

Registry

Crossref · 10.1097/ftd.0000000000000952

Cites

567 of 567 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 570 references

Research works printed but not linked: 1

  1. Zhou, 2019, Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based pharmacokinetic modelling, Eur J Pharm Sci, 139, 105061, 10.1016/j.ejps.2019.105061 · DOI

Cited by

See all 82

Metadata

Authors
Kably, B., Launay, M., Derobertmasure, A., Lefeuvre, S., Dannaoui, E., & Billaud, E. M.
Affiliations
  • Université Paris Cité (FR)
  • Centre Hospitalier Universitaire de Saint-Étienne (FR)
  • Assistance Publique – Hôpitaux de Paris (FR)
  • Centre Hospitalier Universitaire de Poitiers (FR)
  • Faculté de Médecine, Université de Paris, Paris, France;
Corresponding author
  • Kably, Benjamin
  • Derobertmasure, Audrey
  • Billaud, Eliane M.
Venue
Therapeutic Drug Monitoring
Published
2022-02
Volume
44
Issue
1
Pages
166-197
ISSN
0163-4356 (ISSN-L)
OpenAlex
W4200470547
Cited by
81
References
570
Citations by year
2026: 17 · 2025: 17 · 2024: 23 · 2023: 17 · 2022: 5
FWCI
1.35
Type
journal article
Language
en
Open access
closed
Locations
  • Therapeutic Drug Monitoring (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords
antifungal agents, invasive fungal infections, drug-drug interactions, azole antifungals, voriconazole, isavuconazole, fluconazole, amphotericin B, echinocandins, posaconazole, pharmacokinetics, antifungal prophylaxis, Aspergillus, Mucorales, Candida, central nervous system fungal infection, immunocompetent patient, physiologically based pharmacokinetic modeling
MeSH terms
Antifungal Agents, Humans, Fluconazole, Drug Monitoring, Itraconazole, Voriconazole

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antifungal Drugs TDM: Trends and Update. https://app.cochat.ai/papers/10.1097/ftd.0000000000000952
The paper
Kably, B., Launay, M., Derobertmasure, A., Lefeuvre, S., Dannaoui, E., & Billaud, E. M. (2022). Antifungal Drugs TDM: Trends and Update. Therapeutic Drug Monitoring. https://doi.org/10.1097/ftd.0000000000000952

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.